Sigma opioid receptors; SKF-10,047 update

Area of Science:

• Pharmacology
• Neuroscience
• Receptor Binding Assays

Background:

• Opioid drugs like morphine exert profound effects on the central nervous system.
• Understanding the specific receptor interactions of opioid compounds is crucial for developing targeted therapeutics.
• The role of sigma receptors in opioid pharmacology remains an area of active investigation.

Purpose of the Study:

• To investigate the distinct pharmacological properties of the enantiomers of SKF-10,047.
• To elucidate the receptor mechanisms underlying the psychotogenic and opioid effects of SKF-10,047.
• To differentiate the roles of sigma, mu, and kappa receptors in mediating these effects.

Main Methods:

• Administration of (-)- and (+)-SKF-10,047 to naive and morphine-dependent rats.
• Assessment of electroencephalogram (EEG) and behavioral responses.
• Induction and assessment of naloxone-precipitated withdrawal.
• In vitro receptor binding assays using [3H] dihydromorphine.

Main Results:

• (-)-SKF-10,047 blocked morphine's effects, precipitated withdrawal, induced physical dependence, and displaced [3H] dihydromorphine.
• (+)-SKF-10,047 did not induce dependence or displace [3H] dihydromorphine.
• Pharmacodynamic dissociation suggests sigma receptor involvement in psychotogenic effects, not opioid characteristics.

Conclusions:

• The opioid and dependence-producing effects of SKF-10,047 are stereospecific and likely mediated by mu or kappa receptors.
• Sigma receptor activation by (-)-SKF-10,047 is associated with psychotogenic properties, separate from opioid actions.
• These findings highlight the differential roles of receptor subtypes in the complex pharmacology of SKF-10,047.